Reproducibility of dalbavancin MIC test results and an updated surrogate accuracy analysis of vancomycin MIC values to infer dalbavancin susceptibility (2014)
- 9 February 2016
- journal article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 86 (2) , 249-251
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancinDiagnostic Microbiology and Infectious Disease, 2015
- Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studiesAnnals of Clinical Microbiology and Antimicrobials, 2015
- Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin InfectionNew England Journal of Medicine, 2014
- Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011)Diagnostic Microbiology and Infectious Disease, 2013
- New LipoglycopeptidesDrugs, 2010
- Activities of Dalbavancin against a Worldwide Collection of 81,673 Gram-Positive Bacterial IsolatesAntimicrobial Agents and Chemotherapy, 2009
- Comparison of Dalbavancin MIC Values Determined by Etest (AB BIODISK) and Reference Dilution Methods Using Gram-Positive OrganismsJournal of Clinical Microbiology, 2006
- Selection of a Surrogate Agent (Vancomycin or Teicoplanin) for Initial Susceptibility Testing of Dalbavancin: Results from an International Antimicrobial Surveillance ProgramJournal of Clinical Microbiology, 2006
- Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off valuesClinical Microbiology and Infection, 2006
- Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptideInternational Journal of Antimicrobial Agents, 2004